Novo Nordisk is reframing GLP-1 drugs as “weight loss” products and shifting how it refers to people using them—from “patients” to “customers,” according to STAT+. The report points to global advertising language and changes on Wegovy’s website as part of a broader positioning move that could affect how payers, regulators, and competitors interpret the drugs’ intended use and target populations.